CytomX Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CytomX Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2023.
  • CytomX Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $4.11M, a 31.6% increase year-over-year.
  • CytomX Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $6.71M.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$6.48M, a 93.6% increase from 2022.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$101M, a 12.7% increase from 2021.
  • CytomX Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$116M, a 44.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.